Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
BRD8 is a therapeutic vulnerability for overcoming resistance to dual ER/HER2 blockade therapy in HR+/HER2+ breast cancer
<p>.rda file for Seurat object of scRNA-seq data from BT474 breast cancer cell lines treated with DMSO, Neratinib, Fulvestrant, and a combination of Neratinib and Fulvestrant.</p>
Rawdata EMS 24 hr mortality
<p>Rawdata EMS 24 hr mortality</p>
Supplementary material 1 from: Hubancheva A, Bozicevic V, Morinière J, Goerlitz HR (2023) DNA metabarcoding data from faecal samples of the lesser (Myotis blythii) and the greater (Myotis myotis) mouse-eared bats from Bulgaria. Metabarcoding and Metagenomics 7: e106844. https://doi.org/10.3897/mbmg.7.106844
Metabarcoding data from M. myotis and M. blythii from Bulgaria
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
ClinicalTrials.gov study NCT04293393. IPD Sharing: NO. Countries: 1. Publications: 0.
Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer
ClinicalTrials.gov study NCT05512780. IPD Sharing: NO. Countries: 0. Publications: 1.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov study NCT06369285. IPD Sharing: YES. Countries: 3. Publications: 0.
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
ClinicalTrials.gov study NCT04256941. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
ClinicalTrials.gov study NCT07288359. IPD Sharing: YES. Countries: 2. Publications: 0.
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT02679755. IPD Sharing: YES. Countries: 2. Publications: 0.
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatme
ClinicalTrials.gov study NCT03439046. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Increasing Exercise Adherence After Percutaneous Coronary Intervention With the Fitbit Charge HR Device
ClinicalTrials.gov study NCT02788929. IPD Sharing: Not stated. Countries: 0. Publications: 9.
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
ClinicalTrials.gov study NCT06144944. IPD Sharing: YES. Countries: 1. Publications: 0.
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
ClinicalTrials.gov study NCT05452798. IPD Sharing: NO. Countries: 1. Publications: 0.
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
ClinicalTrials.gov study NCT04937660. IPD Sharing: NO. Countries: 5. Publications: 0.
Feasibility of Fasting & Exercise in Pts With HR+ MBC
ClinicalTrials.gov study NCT04708860. IPD Sharing: YES. Countries: 1. Publications: 0.
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced
ClinicalTrials.gov study NCT02964507. IPD Sharing: YES. Countries: 7. Publications: 0.
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aroma
ClinicalTrials.gov study NCT05038735. IPD Sharing: YES. Countries: 17. Publications: 0.
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
ClinicalTrials.gov study NCT03910712. IPD Sharing: NO. Countries: 0. Publications: 1.
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
ClinicalTrials.gov study NCT03280563. IPD Sharing: Not stated. Countries: 3. Publications: 0.
PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement
ClinicalTrials.gov study NCT02244619. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.